ABSTRACT
Objective@#To investigate the effect of modified Bianchi (single incision in the midline of the scrotum) orchiopexy (MBO) versus that of traditional surgery in the treatment of median or low cryptorchidism.@*METHODS@#Eighty-two children with median or low cryptorchidism were treated from February 2013 to February 2014, 46 (53 testes) by MBO and the other 36 by the traditional method of inguinal incision (control, 40 testes). Comparisons were made in the operation time and postoperative complications between the two surgical strategies.@*RESULTS@#The mean operation time was significantly shorter in the MBO group than in the control ([25±6] vs [35±4] min, P0.05). The incision scar was obvious in all the controls, with 1 case of postoperative inguinal hematoma, but almost invisible in all the MBO cases.@*CONCLUSIONS@#Modified Bianchi orchiopexy is superior to traditional surgery in the treatment of median or low cryptorchidism for its advantages of short operation time, few complications, and satisfactory appearance of the healed incision.
Subject(s)
Child , Humans , Infant , Male , Cryptorchidism , General Surgery , Groin , General Surgery , Hematoma , Operative Time , Orchiopexy , Methods , Postoperative Complications , Postoperative Period , Scrotum , General Surgery , Surgical WoundABSTRACT
<p><b>OBJECTIVE</b>To investigate the correlation between the expression of the kinase insert domain-containing receptor (KDR) and the histological grade of prostate adenocarcinoma.</p><p><b>METHODS</b>Forty-eight samples of prostate adenocarcinoma tissues and 20 samples of benign prostatic hypertrophy (BPH) tissues were studied by LsAB immunohistochemical staining.</p><p><b>RESULTS</b>The positive expression rate of KDR was 73% in prostate adenocarcinoma and 30% in BPH. The expression of KDR was stronger in prostate adenocarcinoma, and there was no relationship between staining intensity and the histological grade of carcinoma.</p><p><b>CONCLUSION</b>KDR, expressed more highly in prostate adenocarcinoma, promises to be a new target in the treatment of prostate adenocarcinoma.</p>